Quote this publication Share Print

XELJANZ (tofacitinib), anti-JAK 1 and 3

RHEUMATOLOGY - New medicinal product
Opinions on drugs - Posted on Jan 18 2018

Reason for request

Inclusion

No clinical benefit demonstrated in the treatment of rheumatoid arthritis (RA) after failure of one or more disease-modifying antirheumatic drugs (DMARD)

  

  • XELJANZ has a Marketing Authorisation in the treatment of rheumatoid arthritis (RA) after failure of one or more DMARDs.  It is administered orally, twice a day.
  • It is a second-line treatment after failure of conventional DMARDs such as methotrexate (MTX),  as a third-line treatment (after failure of a biological DMARD) or beyond (failure of multiple conventional and/or biological DMARDs).
  • Its non-inferiority has been demonstrated in combination with MTX compared with adalimumab in second-line (after MTX failure); its superiority has not been demonstrated. XELJANZ has not been compared to available third-line alternatives (in particular tocilizumab, abatacept, rituximab).
  • There are concerns in terms of long-term safety, in particular in relation to risks of infection and cardiovascular and carcinogenic risks.

 

 

 

 


Actual benefit

Important

-


Improvement in actual benefit

V (absence)

-


Therapeutic use

-

Contact Us

Évaluation des médicaments